This reproductive health company's weekly contraceptive patch can reach millions of women thanks to a partnership with afaxys

Princeton, nj / accesswire / july 19, 2023 / agile therapeutics, inc.'s (nasdaq:agrx) partnership with afaxys pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million net annual revenue target for 2023. the companies teamed up last year to make twirla® (levonorgestrel and ethinyl estradiol) transdermal system, agile's low-dose contraceptive patch available to the more than 15,000 health centers that afaxys serves.
AGRX Ratings Summary
AGRX Quant Ranking